Lestaurtinib inhibition of the jak/stat signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Diaz, Tania ^a   Navarro, Alfons ^a   Ferrer, Gerardo ^b   Gel, Bernat ^c   Gaya, Anna ^b   Artells, Rosa ^a   Bellosillo, Beatriz ^d   Garcia Garcia, Mar ^d   Serrano, Sergi ^d   Martínez, Antonio ^b   Monzo, Mariano ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; JANUS KINASE 2; LESTAURTINIB; MESSENGER RNA; PROTEIN BCL XL; STAT3 PROTEIN; STAT5 PROTEIN; CARBAZOLE DERIVATIVE; JANUS KINASE; PROTEIN KINASE INHIBITOR; STAT PROTEIN;

ADULT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; APOPTOSIS; BLOTTING, WESTERN; CARBAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HODGKIN DISEASE; HUMANS; JANUS KINASES; MALE; PROTEIN KINASE INHIBITORS; STAT TRANSCRIPTION FACTORS;

EID: 79955394571     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018856     Document Type: Article

References (26)

1. Küppers R, (2009) The biology of Hodgkin's lymphoma. Nature reviews Cancer 9: 15-27.
2. Darnell J, Kerr I, Stark G, (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421.
3. Gozgit JM, Bebernitz G, Patil P, Ye M, Parmentier J, et al. (2008) Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. The Journal of biological chemistry 283: 32334-32343.
4. Joos S, Kupper M, Ohl S, von Bonin F, Mechtersheimer G, et al. (2000) Genomic Imbalances Including Amplification of the Tyrosine Kinase Gene JAK2 in CD30+ Hodgkin Cells. Cancer Res 60: 549-552.
5. Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, et al. (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25: 2679-2684.
6. Levine RL, Pardanani A, Tefferi A, Gilliland DG, (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature reviews Cancer 7: 673-683.
7. Melzner I, Weniger MA, Menz CK, Möller P, (2006) Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 20: 157-158.
8. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, et al. (2001) STAT3 is constitutively activated in Hodgkin cell lines. Blood 98: 762-770.
9. Navarro A, Diaz T, Martinez A, Gaya A, Pons A, et al. (2009) Regulation of JAK2 by miR-135a: prognostic impact in classical Hodgkin lymphoma. Blood 114: 2945-2951.
10. Evens AM, Hutchings M, Diehl V, (2008) Treatment of Hodgkin lymphoma: the past, present, and future. Nature clinical practice Oncology 5: 543-556.
11. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, et al. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. The New England journal of medicine 327: 1478-1484.
12. Buglio D, Georgakis G, Younes A, (2007) Novel small-molecule therapy of Hodgkin lymphoma. Expert review of anticancer therapy 7: 735-740.
13. Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, et al. (2003) Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. International Journal of Cancer 103: 489-495.
14. Pardanani A, (2008) JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22: 23-30.
15. Anas Younes MF, McLaughlin Peter, Copeland AmandaR, de Castro Faria Silvana, Wood Jeanette, Ethirajulu Kantharaj, Zhu HuanJ, (2009) Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity. Blood 114: 588.
16. Shabbir M, Stuart R, (2010) Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside. Expert Opinion on Investigational Drugs 19: 427-436.
17. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, et al. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671.
18. Fromm JR, Kussick SJ, Wood BL, (2006) Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. Am J Clin Pathol 126: 764-780.
19. Fromm JR, Thomas A, Wood BL, (2009) Flow cytometry can diagnose classical hodgkin lymphoma in lymph nodes with high sensitivity and specificity. Am J Clin Pathol 131: 322-332.
20. Jemal A, Center MM, Ward E, Thun MJ, (2009) Cancer occurrence. Methods in molecular biology (Clifton, NJ) 471: 3-29.
21. Horning MF S, DeVos S, Borchmann P, Illidge T, Engert A, Arai AY S, (2008) Defining a population of hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol 19: 120-121.
22. Horning SJ, (2007) Risk, cure and complications in advanced hodgkin disease. Hematology 1: 197-203.
23. Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, et al. (2009) Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 22: 476-487.
24. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, et al. (1998) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 16: 1383-1390.
25. Chu WS, Aguilera NS, Wei MQ, Abbondanzo SL, (1999) Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12. Hum Pathol 30: 1065-1070.
26. Bai M, Papoudou-Bai A, Horianopoulos N, Grepi C, Agnantis NJ, et al. (2007) Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas. Hum Pathol 38: 103-113.